comparemela.com

Halo Lido Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Citius Pharmaceuticals, Inc Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial CRANFORD, N.J., Feb. 14, 2024 /PRNewswire/ Citius.

New jerseyUnited statesGreg salsburgIlanit allenRobert smithCitius pharmaLeonard mazurDrug administrationCitius pharmaceuticals incSecurities exchangeCitius oncology incCompany nasdaqPrnewswire citius pharmaceuticals incInvestor relations for citius pharmaceuticalsDevelopment rd expensesExchange commission

Citius Pharmaceuticals, Inc Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.

New jerseyUnited statesLeonard mazurGreg salsburgIlanit allenRobert smithCitius pharmaCitius pharmaceuticals incDevelopment rd expensesSecurities exchangePrnewswire citius pharmaceuticals incDrug administrationCitius oncology incCompany nasdaqInvestor relations for citius pharmaceuticalsExchange commission

Citius Pharmaceuticals, Inc Reports Fiscal Full Year 2023 Financial Results and Provides Business Update

Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024 CRANFORD, N.J., Jan. 2, 2024 /PRNewswire/ Citius.

New jerseyUnited statesCitius pharmaLeonard mazurIlanit allenGreg salsburgUniversity of minnesotaExchange commissionCitius oncology incCompany nasdaqMasonic cancer centerDevelopment rd expensesUniversity of pittsburgh medical centerSecurities exchangeCitius pharmaceuticals incInvestor relations for citius pharmaceuticals

Citius Pharmaceuticals, Inc Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.

New jerseyUnited statesLeonard mazurIlanit allenGreg salsburgCitius pharmaceuticals incPrnewswire citius pharmaceuticals incCompany nasdaqSecurities exchangeExchange commissionJersey technology business tax certificate transfer programDevelopment rd expensesChief executive officerHalo lido phaseCitius pharmaceuticalsFast track

Citius Pharmaceuticals, Inc Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

$33.3 million in cash and cash equivalents as of June 30, 2023; runway through August 2024 CRANFORD, N.J., Aug. 14, 2023 /PRNewswire/ Citius Pharmaceuticals, Inc. , a late-stage.

New jerseyUnited statesGreg salsburgLeonard mazurIlanit allenJersey technology business tax certificate transfer programExchange commissionCitius pharmaceuticals incSecurities exchangeDevelopment rd expensesPrnewswire citius pharmaceuticals incCompany nasdaqChief executive officerHalo lido phaseCitius pharmaceuticalsFast track

vimarsana © 2020. All Rights Reserved.